Rani Therapeutics Promotes Alireza Javadi to Chief Technical Officer

Written by Emily J. Thompson, Senior Investment Analyst

Updated: 2d ago

0mins

Rani Therapeutics announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. Prior to the promotion to Chief Technical Officer, Alireza served as Vice President, Technical Operations, where he was responsible for Rani's R&D, manufacturing, and automation teams

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RANI?" and start using high-conviction signals backed by rigorous historical data.

RANI

$1.21+Infinity%1D

Analyst Views on RANI

Wall Street analysts forecast RANI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RANI is 10.00 USD with a low forecast of 9.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Analyst Rating

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.280

Low

9.00

Averages

10.00

High

11.00

Current: 1.280

Low

9.00

Averages

10.00

High

11.00

H.C. Wainwright

Brandon Folkes

Buy

initiated

$11

2025-10-21

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$11

AI Analysis

2025-10-21

initiated

Buy

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. The firm believes the company has "three significant value drivers," its platform technology RaniPill, a recently announced collaboration agreement with Chugai Pharmaceutical for the development of a hemophilia product, and potentially an additional five drug targets, as well as RT-114, an oral GLP-1/GLP-2 dual agonist candidate. It expects data readouts on RT-114 to be the biggest driver of near-term value creation for Rani shares.

Maxim Group

Maxim

Buy

maintain

$5 -> $10

2025-10-20

Reason

Maxim Group

Maxim

Price Target

$5 -> $10

2025-10-20

maintain

Buy

Reason

Maxim raised the firm's price target on Rani Therapeutics to $10 from $5 and keeps a Buy rating on the shares after the company announced a licensing deal with Chugai Pharmaceutical for RaniPill technology and a concurrent private placement to raise $60M in proceeds. The Chugai deal offers both non-dilutive financing as well as "key validation" for RaniPill, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RANI

Unlock Now

About RANI

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

GET FREE REAL TIME NOTIFICATIONS

Stock Monitor for RANI?

Get Started Free

FREE STOCK RECOMMENDATIONS DAILY

Stock Bullish Tomorrow

Get Started Free

70% BACKTESTED ACCURACY!

Should I Buy RANI?

Get Started Free

Top News

Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead

Nov 04 2025NASDAQ.COM

Tactile Systems Technology Inc. (TCMD): The company saw a 22.13% increase in after-hours trading after reporting a strong Q3 2025 earnings with net income rising to $8.2 million and revenue climbing 17% year-over-year. They also raised their full-year revenue guidance to $317 million - $321 million.
Biodesix Inc. (BDSX): Shares surged 10.57% after the company reported a 20% increase in Q3 2025 revenue to $21.8 million and a narrowed net loss. They raised their full-year revenue forecast to $84 million - $86 million, indicating sustained growth.
Exact Sciences Corp. (EXAS): The stock rose 7.78% following a Q3 2025 earnings report showing a 20% revenue increase to $851 million and a significantly narrowed net loss. The company also raised its full-year revenue guidance to $3.220 - $3.235 billion.
Rani Therapeutics (RANI) and Grace Therapeutics Inc. (GRCE): Rani's shares increased 5.12% ahead of a presentation at ObesityWeek 2025, while Grace's stock rose 6.11% following the full exercise of common warrants tied to a previous funding round, securing additional capital for their drug candidate.

an image of Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead

Insider Buying Update for Tuesday, October 28: RANI and KO

Oct 28 2025NASDAQ.COM

Rani Therapeutics Holdings Insider Purchase: Mir Imran, the CEO of Rani Therapeutics Holdings, bought 2,083,334 shares of RANI for $1.26 million, resulting in a 228.9% gain based on the current trading price.
Coca-Cola Insider Purchase: Director Max R. Levchin purchased 14,267 shares of Coca-Cola for $998,676, marking his first purchase in the past year, with Coca-Cola's stock up 0.5% on the same day.

an image of Insider Buying Update for Tuesday, October 28: RANI and KO

Rani Therapeutics Promotes Alireza Javadi to Chief Technical Officer

Trade with 70% Backtested Accuracy

Analyst Views on RANI

About RANI

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Worst Performing Consumer Staples Stocks in January 2026

Vanguard Tech ETF Faces AI Investment Gaps

Biotech Stocks Soar in After-Hours Trading: TCMD, BDSX, and EXAS Take the Lead

Insider Buying Update for Tuesday, October 28: RANI and KO

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch